Mass Cytometry, Imaging Mass Cytometry, and Multiplexed Ion Beam Imaging Use in a Clinical Setting

Raymond D Devine; Gregory K Behbehani

doi:10.1016/j.cll.2021.03.008

Mass Cytometry, Imaging Mass Cytometry, and Multiplexed Ion Beam Imaging Use in a Clinical Setting

Clin Lab Med. 2021 Jun;41(2):297-308. doi: 10.1016/j.cll.2021.03.008. Epub 2021 Apr 24.

Authors

Raymond D Devine¹, Gregory K Behbehani²

Affiliations

¹ Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Comprehensive Cancer Center, Columbus, OH, USA.
² Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Comprehensive Cancer Center, Columbus, OH, USA. Electronic address: Gregory.Behbehani@OSUMC.edu.

PMID: 34020765
DOI: 10.1016/j.cll.2021.03.008

Abstract

Mass cytometry (MC), imaging mass cytometry (IMC), and multiplexed ion beam imaging (MIBI) represent a new generation of tools to understand increasingly complex systems. Although these technologies differ in their intended applications, with MC being most similar to flow cytometry, and IMC/MIBI being similar to immunohistochemistry, they all share a time of flight mass spectrometry (TOF MS) platform. These TOF MS platforms use metal conjugated antibodies as opposed to fluorophores, increasing the measurable parameters up to approximately 50 with a theoretic limit approximately 100 parameters. These tools are being adapted to understand highly complex systems in basic and clinical research.

Keywords: High-parameter data analysis; Imaging mass cytometry; Mass cytometry; Mass spectroscopy time of flight; Multiplex ion beam imaging.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antibodies
Diagnostic Imaging*
Flow Cytometry
Image Cytometry*
Mass Spectrometry

Substances

Antibodies